Skip to content

Released Aug 10, 2023, before the open

10-Q filed Aug 10, 2023, 41 days after period end · 0001764013-23-000092

Q1 2024 · 10-Q
Revenue—
Net Income-$73.94MN/M vs Q1 2023N/M vs Q4 2023
EPS Diluted-$0.57N/M vs Q1 2023no prior Q4 2023 on file
Operating Cash Flow-$47,370,000N/M
Free Cash Flowderived-$47,415,000N/M

What the release said

The release

Same quarter

MetricQ1 2024Q1 2023Q1 2022Q1 2019
Net Income-$73.94M-$40.37M-$30.47M-$20.06M
EPS Diluted-$0.57-$0.35-$0.31-$0.52

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Immunovant, Inc. · CIK 1764013 · Engraved from SEC EDGAR